I've Replaced 840 Knees. Here's What I Was Never Supposed to Tell You.

If you have knee pain that's been hanging around for more than three months —

If you've been using Voltarol, Deep Heat, or ibuprofen gel and found yourself wondering why the relief runs out before lunch —

If a GP, a physio, or a consultant has told you to "manage it" and you've accepted that as an answer —

Then what I'm about to tell you is going to make you angry.

Not at me.

At a system that had the information this entire time and no incentive to share it with you.

I spent twenty-four years operating on knees. I placed over eight hundred and forty of them on an operating table, opened the joint, worked inside it, and closed it back up again. I know what an arthritic knee looks like, feels like, and how it got there.

And what I know — what I've known for years and only feel free to say now that I've retired — is this:

I need you to read this before you book another physio appointment. Before you reach for that tube of Voltarol. Before you accept one more "management plan" that doesn't mention the inflammatory pathway driving your knee pain every single morning.

It'll take five minutes. It might change everything.

Who I Am — And Why I'm Done Staying Quiet

My name is James Hartley.

I trained at the Royal Victoria Infirmary in Newcastle, specialised in orthopaedic surgery, and spent the majority of my career at a major NHS trust in Manchester performing knee and hip replacements. In my last five years before retirement I also ran a private clinic alongside my NHS work.

I've operated on teachers, builders, retired nurses, former athletes, desk workers. I've replaced knees in people in their late forties and knees in people in their eighties.

And for most of my career, when those patients asked me — usually before surgery, usually with a kind of desperate hope — "Is there anything else I could have done? Anything that would have helped before it got to this?" —

I told them no.

I told them the treatment pathways had been followed correctly. That they'd done what they were supposed to do. That osteoarthritis was a progressive condition and surgery was the appropriate intervention at this stage.

I believed most of that when I said it.

What I didn't say — what I didn't fully understand until two years before I retired — was that the treatment pathways we were following were built around a single arm of the inflammatory cascade driving their knee pain.

One arm. Not both.

And then I retired. And I started reading.

The Patient I Can't Stop Thinking About

Nothing shifted my perspective more than a woman I'll call Dorothy.

Sixty-four years old. Retired primary school headmistress from Altrincham. She came to see me with advanced osteoarthritis in her right knee — bone-on-bone contact, cartilage worn through on the medial side, the X-rays exactly what you'd expect in someone whose inflammation had been slowly destroying joint tissue for years.

She'd been managing her knee pain for five and a half years.

Five and a half years of Voltarol, prescribed by her GP. Of physiotherapy — two separate courses, NHS and then private when the NHS list ran too long. Of a heated support, a copper brace, a prescription for naproxen that had to be stopped after four months because of her stomach. Of cortisone injections — she'd had three. Each one bought her three or four months of relief, then she'd return to baseline.

"I did everything they told me," she said, sitting in my consultation room. "Every single thing. Twice."

I looked at her notes. She was telling the truth.

She went home that day knowing she was on my operating list for a total knee replacement.

That night I sat at my desk and looked at five and a half years of management documentation and thought about something I'd been reading in the research literature.

I replaced Dorothy's knee four months later.

The procedure went well. She has a good outcome.

But I think about those five and a half years. I think about what might have been different if someone had addressed the right part of the problem, at the tissue level, consistently, from the beginning.

What I Found When I Started Looking in the Right Place

The discovery that changed how I think about this didn't come from a conference.

It came from a patient.

Twelve months before I retired, a woman came in for a pre-operative assessment. She was sixty-one, same diagnosis as Dorothy — right knee OA, scheduled for unicompartmental replacement. I'd seen her initial assessment notes eight months earlier. I expected a standard pre-operative picture.

Her joint was measurably different from what the assessment had predicted.

The inflammatory markers were lower than I'd expected. The soft tissue quality around the joint was better. She was moving more freely than the assessment notes had suggested she would be.

I asked what had changed.

"I started using something called Kinzeno," she said. "A botanical gel. I've been using it twice a day for about seven months."

I'm an orthopaedic surgeon. I do not — by training or by instinct — take botanical gels seriously.

But I was also looking at a joint that was in better condition than I'd expected. And I'm a scientist before I'm a surgeon. So I went home that evening and looked up every ingredient in the product's profile.

What I found in the pharmacology literature stopped me cold.

The Inflammatory Pathway Your Management Plan Is Missing

Here's what most knee pain patients are never told.

Inflammation in an arthritic joint doesn't run on a single pathway. It runs on two primary ones.

Pathway One: The COX cascade. This produces prostaglandins — the body's acute inflammatory signal. This is the pathway that NSAIDs address. This is what Voltarol is doing when it gives you a few hours of relief. It's suppressing this pathway's output, and it works. For as long as the drug is active.

Then it wears off. And the pathway starts again.

Pathway Two: The 5-LOX cascade. This produces leukotrienes — specifically leukotriene B4, which is the primary mediator ofchronic, sustainedinflammation in arthritic joint tissue.

This pathway doesn't care about Voltarol. It doesn't care about NSAIDs. It operates via a completely different enzyme — 5-lipoxygenase — and a different branch of the inflammatory cascade entirely.

And this pathway is what keeps your knee inflamed between doses. This is what's grinding your cartilage down while you sleep. This is the inflammatory environment that, after five years, produces the X-ray that puts you on my operating list.

Think of it this way.

And this is why, when my patient asked me what had changed, I found myself looking at a joint that had spent seven months with something actively working on that pathway — and comparing it to Dorothy's joint after five and a half years without it.

The Four Things That Have Been Offered to You — And Why Three of Them Miss the Point

I'm not here to tell you everything you've tried is worthless.

Some of it has value. Let me be precise.

Option 1: NHS physiotherapy.

Good physiotherapy is genuinely good. Manual therapy, specific loading protocols, education — in the right hands, for the right patient, this changes outcomes. The problem is access. Twelve to twenty-two weeks to first appointment. Six sessions, three weeks apart. And no physiotherapist in the country can give you a daily practice that addresses joint tissue inflammation at the biochemical level.

The gap between sessions is where cartilage loses ground.

Option 2: NSAIDs — Voltarol, ibuprofen gel, naproxen.

These address the COX pathway. They reduce the acute pain signal. For short-term, acute presentations, they are the appropriate tool. For daily long-term use — the kind most of you are doing — they come with GI and renal considerations, and they do not address the leukotriene pathway that's driving your chronic inflammation.

They silence the alarm. Every few hours. Without touching the fire.

Option 3: Corticosteroid injections.

I've administered hundreds. They work — for three to six months in many patients. Then the inflammatory environment reasserts itself and the relief fades. They are not a sustainable daily management tool. The evidence on repeated injections beyond three is also mixed.

Option 4: Consistent botanical application to the tissue, twice daily, targeting the 5-LOX pathway directly.

This is what none of the options above do. And this is what the research literature — which I spent the final year of my career reading properly for the first time — shows is both possible and achievable outside a clinical setting.

This is the option that was available to Dorothy for five and a half years before she reached my operating table.

Nobody mentioned it.

Let me tell you why.

The Research That Pharmaceutical Companies Would Prefer You Didn't Know About

Boswellia Serrata.

The resin of the Boswellia tree has been used in medicine for centuries — in Ayurvedic practice, in African traditional medicine, in historical European apothecary. For most of modern medical history, this was filed under "folk remedy" and largely ignored by Western pharmacology.

Then the research started coming in.

Boswellic acids — specifically a compound called AKBA, acetyl-11-keto-β-boswellic acid — are documented inhibitors of 5-lipoxygenase. The enzyme that drives the leukotriene B4 cascade. The cascade that no NSAID touches.

Not one study. Meta-analyses. Multiple randomised controlled trials. Published in mainstream rheumatology and pharmacology journals. This is peer-reviewed evidence. This is not fringe naturopathy.

Pharmaceutical companies have been examining Boswellic acids for years — because the mechanism is real and the evidence is there. The problem, from a commercial perspective, is that Boswellia is a plant. You cannot patent a plant. You cannot build a prescription revenue model around it. So the research exists, and the commercial incentive to bring it into clinical practice does not.

Your GP has ten minutes. Their prescribing decisions are guided by NICE pathways. Boswellia Serrata is not on a NICE pathway. So it is not in the conversation.

And the knee deteriorates.

What Happens When You Actually Address Both Pathways

The patient who showed me what was possible was sixty-one years old.

She'd been using a topical botanical gel — twice daily, massaged directly into the knee — for seven months before her pre-operative assessment. The gel was called Kinzeno. It contained Boswellia Serrata as its primary active botanical, combined with Arnica Montana, MSM, and Magnesium.

Let me explain why that combination matters.

Boswellia Serrata (AKBA) addresses the leukotriene cascade. Interrupts the 5-LOX enzyme pathway that drives chronic joint inflammation. This is the fire, finally getting something aimed at it.

Arnica Montana is an anti-inflammatory botanical with a genuine evidence base — used in professional sports medicine and in post-surgical settings precisely because it works on soft tissue inflammation. The soft tissue around an arthritic knee is as much a source of pain as the joint itself.

MSM (Methylsulfonylmethane) provides bioavailable organic sulphur — a structural component of cartilage. Your cartilage needs this. Your body uses it in ongoing maintenance and repair. Most people with chronic OA are not getting what the joint tissue needs to sustain itself.

Magnesium plays a well-documented role in muscle function and in reducing soft tissue tension around joints. A significant proportion of knee pain is amplified by muscle guarding and compensatory tension in the structures surrounding the joint — this addresses that layer.

Four compounds. Four different tissue targets. All working simultaneously.

And critically — the application is massage-based. You work these compounds into the tissue actively, twice daily. This isn't passive absorption. Active massage increases local circulation, improves penetration, and maintains the manual tissue engagement that was the useful part of physiotherapy — but every single day, not once every three weeks.

I cannot tell you that Kinzeno would have changed Dorothy's outcome. I wasn't there for Dorothy's five and a half years.

But I can tell you that addressing both inflammatory pathways — the COX cascade AND the leukotriene cascade — at the tissue level, every day, is so obviously the correct approach that I am still angry with myself for not asking these questions twenty years earlier.

What Thirty Thousand People Are Saying

Over 30,000 people in the UK have now used Kinzeno. The verified customer rating is 4.9 out of 5 stars.

Here is what they are saying.

The Reason This Costs a Fraction of What It Should

A proper clinical protocol for addressing both inflammatory pathways in arthritic knee tissue — botanical intraarticular injections, targeted manual therapy, comprehensive supplementation — costs upwards of £2,000 per quarter at a private clinic.

Most people spend far more than that on treatments that don't address the right pathway.

Dorothy spent five and a half years and several thousand pounds on management that left the leukotriene cascade running.

Kinzeno is available at70% offthrough this page.

Less than one private physiotherapy session. Less than two months of Voltarol tubes that you'll buy again next month because the inflammation will still be there in the morning.

And unlike those options —Kinzeno comes with a full 30-day money-back guarantee.

Use it every morning and evening for thirty days. Give it a genuine chance. If your mornings aren't different — if you can't point to a meaningful change in how your knee feels when you get out of bed — contact them and get every penny back. No forms. No arguments.

A company only offers that guarantee if they have confidence in the product.

Their refund rate is under 1%.

How to Order (It Takes Two Minutes)

Click the button on this page. Confirm the 70% discount is live — it is subject to available stock at this price.

At minimum, order a two-month supply. The Boswellia research is clear that the 5-LOX inhibition compounds over consistent daily use — you want to be at week four, where the effect on your inflammatory baseline becomes unmistakable, and you want enough product to get there without interruption.

Most people order three months. A significant number order for a spouse or parent at the same time.

If You're Still Not Sure, Read This

Knee osteoarthritis does not stay the same.

I know this because I spent twenty-four years watching what happens when the leukotriene cascade runs uninterrupted.

The cartilage continues to degrade. The bone contact progresses. The soft tissue guarding worsens. The mornings get harder. The things you've quietly stopped doing accumulate.

And eventually, someone like me is looking at your X-ray and putting you on a list.

I cannot promise Kinzeno changes that trajectory. I'm a surgeon, not a magician, and I don't make clinical claims for products.

What I can tell you is that addressing both inflammatory pathways — COX and leukotriene — at the tissue level, every single day, with compounds that have published peer-reviewed evidence behind them, is the most logical daily practice available to someone with knee OA who wants to do more than silence the alarm while the fire burns.

You have a 30-day guarantee.

You have nothing to lose except the next thirty days of managing it the old way.